Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone...

Form 8-K - Current report

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio...

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically...

Form 4 - Statement of changes in beneficial ownership of securities

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight...

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage...

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data...